Divi’s Laboratories (DIVISLAB) investor relations material

Executive summary

• Q1 FY 2027 saw resilient business performance despite challenging global trade and sourcing conditions, with strong execution in custom synthesis and stable generics volumes.

• Consolidated total income for Q1 FY 2027 was INR 3,144 crores, up from INR 2,529 crores year-over-year.

• Profit before tax rose to INR 1,180 crores from INR 733 crores, and profit after tax increased to INR 902 crores from INR 545 crores year-over-year.

• Standalone total income was INR 3,037 crores, with profit after tax at INR 891 crores for the quarter.

• Standalone revenue grew 10% on a constant currency basis; exports made up 90% of revenue, with Europe and North America accounting for 75% of exports.

Financial highlights

• Standalone revenue from operations for Q1 FY2026-27 was INR 2,974 crores, up from INR 2,357 crores year-over-year.

• Standalone profit before tax was INR 1,165 crores, up from INR 747 crores year-over-year.

• Standalone earnings per share (EPS) for the quarter was INR 33.55, compared to INR 20.95 in Q1 last year.

• Consolidated EPS for the quarter was INR 33.95, up from INR 20.49 year-over-year.

• Forex loss of INR 7 crores in Q1 FY2026-27, compared to a gain of INR 39 crores in Q1 last year.

Outlook and guidance

• Management reiterated expectations for double-digit revenue growth for the full year, with lumpiness possible due to regulatory approvals and project mix.

• Gross and EBITDA margins are expected to be comparable or slightly better than last year, but quarterly fluctuations are anticipated.

• Board approved the unaudited financial results for the quarter ended June 30, 2026.